Login to Your Account



A GAME-CHANGING VALIDATION?

Capricor in $337.5M deal with Janssen for cell therapy product

By Catherine Shaffer
Staff Writer

Tuesday, January 7, 2014
Linda Marban, CEO of Capricor Therapeutics Inc. called a new collaboration between Capricor and Janssen Biotech Inc. a “potentially game-changing validation” of the company’s technology – an allogeneic adult stem cell therapy for heart disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription